NCT05289856View on ClinicalTrials.gov

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

March 1, 2025

Study Completion Date

December 1, 2025

Conditions
Cancer
Interventions
DRUG

combination of Avelumab and Cabozantinib

Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months

Trial Locations (2)

55131

I. Medizinische Klinik und Poliklinik, Endokrinologie und Stoffwechselerkrankungen, Universitätsmedizin Mainz, Mainz

69120

Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

collaborator

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

Johannes Gutenberg University Mainz

OTHER

NCT05289856 - Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3) | Biotech Hunter | Biotech Hunter